The PDUFA target action date is in the fourth quarter of 2026.
Feature|Articles|May 30, 2025
ASCO 2025: What to watch for in GU oncology
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
This year's meeting with feature several notable sessions in prostate cancer, bladder cancer, kidney cancer, and other GU malignancies.
Advertisement
Advertisement
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting is set to kick off on May 30, 2025 in Chicago, Illinois. Spanning 5 days, the conference will feature several notable sessions across prostate cancer, bladder cancer, kidney cancer, and other genitourinary malignancies. In this article, we highlight practice-shifting abstracts that urologists should keep an eye on during this year’s meeting.
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Advertisement
Advertisement